Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial.
Study Goal
The researchers aimed to evaluate the feasibility and efficacy of an adapted Mindfulness-Based Cognitive Therapy (MBCT) program for adolescents and young adults with Inflammatory Bowel Disease (IBD) and comorbid depression.
Results Summary
The study found that MBCT significantly reduced depression and stress, improved active coping, mindfulness, and adaptive coping strategies compared to treatment as usual, with benefits sustained at 20 weeks.
Population
Adolescents and young adults (aged 16-29) with Inflammatory Bowel Disease (IBD) and comorbid depression.
Effective Dosage
Not specified
Duration
8 weeks (post-therapy assessment), with follow-up at 20 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Mindfulness-based cognitive therapy (MBCT) | decrease | depression | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = -6.0; 95%CI = -10.8 to -1.2; P = 0.015 | significantly lower | #1 |
Mindfulness-based cognitive therapy (MBCT) | decrease | stress | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = -5.1; 95%CI = -10.1 to -0.0; P = 0.049 | significantly lower | #2 |
Mindfulness-based cognitive therapy (MBCT) | increase | active coping | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 1.0;95%CI = 0.1-1.9; P = 0.022 | higher | #3 |
Mindfulness-based cognitive therapy (MBCT) | increase | total mindfulness scores | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 10.9;95%CI = 1.1-20.8; P = 0.030 | higher | #4 |
Mindfulness-based cognitive therapy (MBCT) | increase | coping by positive reframing | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 1.1;95%CI = 0.0-2.2; P = 0.043 | improved | #5 |
Mindfulness-based cognitive therapy (MBCT) | increase | coping by planning | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 0.9;95%CI = 0.0-1.9; P = 0.045 | improved | #6 |
Mindfulness-based cognitive therapy (MBCT) | increase | mindful awareness | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 5.2.;95%CI = 2.0-8.5; P = 0.002 | improved | #7 |
Mindfulness-based cognitive therapy (MBCT) | increase | total mindfulness scores | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 10.8.;95%CI = 0.4-21.1; P = 0.042 | improved | #8 |
Mindfulness-based cognitive therapy (MBCT) | decrease | depression | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = -6.3; 95%CI = -11.4 to -1.2; P = 0.015 | significantly lower | #9 |
Mindfulness-based cognitive therapy (MBCT) | decrease | stress | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = -6.0; 95%CI = -11.2 to -0.5; P = 0.032 | significantly lower | #10 |
Mindfulness-based cognitive therapy (MBCT) | increase | active coping | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 0.9;95%CI = 0-1.7; P = 0.05 | increased | #11 |
Mindfulness-based cognitive therapy (MBCT) | increase | mindful awareness | adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression | ∆ = 5.4; 95%CI = 2.1-8.6; P = 0.001 | improved | #12 |
Mindfulness-based cognitive therapy (MBCT) | decrease | depression | AYAs with IBD | - | beneficial in improving | #13 |
Mindfulness-based cognitive therapy (MBCT) | decrease | stress | AYAs with IBD | - | beneficial in improving | #14 |
Mindfulness-based cognitive therapy (MBCT) | increase | mindfulness | AYAs with IBD | - | beneficial in improving | #15 |
Mindfulness-based cognitive therapy (MBCT) | increase | adaptive coping | AYAs with IBD | - | beneficial in improving | #16 |
BACKGROUND: Mindfulness-based cognitive therapy (MBCT) is a promising adjunctive treatment for adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression. OBJECTIVES: This pilot randomised controlled trial (RCT) aimed to evaluate feasibility and efficacy of an adapted MBCT program for AYA, aged 16-29, with IBD. METHODS: Sixty-four AYAs were randomly allocated to MBCT (n = 33) or treatment as usual (TAU) (n = 31). Primary outcome measure was the depression score on Depression, Anxiety and Stress Scale. Secondary outcomes included anxiety, stress, IBD-related quality of life, coping, mindfulness, post-traumatic growth, medication adherence, IBD activity, inflammatory markers, microbiome characteristics and brain functional connectivity. RESULTS: Study recruitment rate was 75%, retention rate 70%, and session attendance 92%. Intention to treat analyses revealed that, compared to TAU group, MBCT group had significantly lower depression (∆ = -6.0; 95%CI = -10.8 to -1.2; P = 0.015) and stress (∆ = -5.1; 95%CI = -10.1 to -0.0; P = 0.049), higher active coping (∆ = 1.0;95%CI = 0.1-1.9; P = 0.022), and total mindfulness scores (∆ = 10.9;95%CI = 1.1-20.8; P = 0.030) at 8 weeks (post-therapy), and improved coping by positive reframing (∆ = 1.1;95%CI = 0.0-2.2; P = 0.043) and planning (∆ = 0.9;95%CI = 0.0-1.9; P = 0.045), mindful awareness (∆ = 5.2.;95%CI = 2.0-8.5; P = 0.002) and total mindfulness scores (∆ = 10.8.;95%CI = 0.4-21.1; P = 0.042) at 20 weeks. On per protocol analysis, MBCT group had significantly lower depression (∆ = -6.3; 95%CI = -11.4 to -1.2; P = 0.015), stress (∆ = -6.0; 95%CI = -11.2 to -0.5; P = 0.032), increased active coping (∆ = 0.9;95%CI = 0-1.7; P = 0.05) at 8 weeks, and mindful awareness (∆ = 5.4; 95%CI = 2.1-8.6; P = 0.001) at 20 weeks. CONCLUSION: In AYAs with IBD, MBCT is feasible and beneficial in improving depression, stress, mindfulness and adaptive coping. It holds promise as an important component of integrated IBD care. Trial registration number ACTRN12617000876392, U1111-1197-7370; Pre-results.